133 related articles for article (PubMed ID: 26215403)
1. Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer.
Wilson AJ; Saskowski J; Barham W; Yull F; Khabele D
J Ovarian Res; 2015 Jul; 8():46. PubMed ID: 26215403
[TBL] [Abstract][Full Text] [Related]
2. Regulation of NF-κB Expression by Thymoquinone; A Role in Regulating Pro-Inflammatory Cytokines and Programmed Cell Death in Hepatic Cancer Cells.
Salah A; Sleem R; Abd-Elaziz A; Khalil H
Asian Pac J Cancer Prev; 2023 Nov; 24(11):3739-3748. PubMed ID: 38019231
[TBL] [Abstract][Full Text] [Related]
3. Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment.
Alexander ET; Minton AR; Peters MC; van Ryn J; Gilmour SK
Oncotarget; 2016 Dec; 7(51):85291-85305. PubMed ID: 27852034
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Thymoquinone on the TNF-α/OTULIN/NF-κB Axis Against Cisplatin-İnduced Testicular Tissue Damage.
Yalçın T; Kaya S; Yiğin A; Ağca CA; Özdemir D; Kuloğlu T; Boydak M
Reprod Sci; 2024 Apr; ():. PubMed ID: 38658488
[TBL] [Abstract][Full Text] [Related]
5. Anticancer Activity of Pterostilbene in Human Ovarian Cancer Cell Lines.
Pei HL; Mu DM; Zhang B
Med Sci Monit; 2017 Jun; 23():3192-3199. PubMed ID: 28664898
[TBL] [Abstract][Full Text] [Related]
6. Effects of 5-fluorouracil, thymoquinone, and mammary stem cells' exosomes on
Abdelfattah-Hassan A; Ibrahim D; Saleh AA; Kishawy ATY; Mohamed RHA; Khater SI
Open Vet J; 2024 Jan; 14(1):525-533. PubMed ID: 38633189
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological NF-κB inhibition decreases cisplatin chemoresistance in muscle-invasive bladder cancer and reduces cisplatin-induced toxicities.
Gil da Costa RM; Levesque C; Bianchi-Frias D; Chatterjee P; Lam HM; Santos C; Coleman IM; Ferreirinha P; Vilanova M; Pinto da Cunha N; Carvalho H; Moreira-Pais A; Faustino-Rocha A; Neto T; Batista da Costa J; Wright JL; Ferreira R; Oliveira PA; Mendes J; Bastos MMSM; Colaço B; Lopes C; Black PC; Sweeney CJ; Nelson PS
Mol Oncol; 2023 Dec; 17(12):2709-2727. PubMed ID: 37533407
[TBL] [Abstract][Full Text] [Related]
8. In Vitro and In Vivo Preventive Effects of Thymoquinone against Breast Cancer: Role of DNMT1.
Kaleem M; Kayali A; Sheikh RA; Kuerban A; Hassan MA; Almalki NAR; Al-Abbasi FA; Anwar F; Omran Z; Alhosin M
Molecules; 2024 Jan; 29(2):. PubMed ID: 38257347
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin increases immune activity of monocytes and cytotoxic T-cells in a murine model of epithelial ovarian cancer.
Hopkins D; Sanchez H; Berwin B; Wilkinson-Ryan I
Transl Oncol; 2021 Dec; 14(12):101217. PubMed ID: 34530192
[TBL] [Abstract][Full Text] [Related]
10. Development of a syngeneic mouse model of epithelial ovarian cancer.
Quinn BA; Xiao F; Bickel L; Martin L; Hua X; Klein-Szanto A; Connolly DC
J Ovarian Res; 2010 Oct; 3():24. PubMed ID: 20958993
[TBL] [Abstract][Full Text] [Related]
11. Investigation of cellular effects of thymoquinone on glioma cell.
Guler EM; Sisman BH; Kocyigit A; Hatiboglu MA
Toxicol Rep; 2021; 8():162-170. PubMed ID: 33489775
[TBL] [Abstract][Full Text] [Related]
12. Synthesised thymoquinone-oxime induces cytotoxicity, genotoxicity and apoptosis in hepatocellular cancer cells:
Guler EM; Bozali K
Nat Prod Res; 2024 May; 38(10):1695-1703. PubMed ID: 37254835
[TBL] [Abstract][Full Text] [Related]
13. The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer.
Lane D; Matte I; Rancourt C; Piché A
J Ovarian Res; 2010 Jan; 3():1. PubMed ID: 20157422
[TBL] [Abstract][Full Text] [Related]
14. Triple Reporter Assay: A Non-Overlapping Luciferase Assay for the Measurement of Complex Macromolecular Regulation in Cancer Cells Using a New Mushroom Luciferase-Luciferin Pair.
Mujawar A; Phadte P; Palkina KA; Markina NM; Mohammad A; Thakur BL; Sarkisyan KS; Balakireva AV; Ray P; Yamplosky I; De A
Sensors (Basel); 2023 Aug; 23(17):. PubMed ID: 37687774
[TBL] [Abstract][Full Text] [Related]
15. SLC11A2: a promising biomarker and therapeutic target in ovarian cancer.
Tian L; Li X; Lai H; Sun T; Li X; Wu L; Wu C; Yao S; Ren Y; He S; Yang G
Sci Rep; 2023 Jan; 13(1):1132. PubMed ID: 36670142
[TBL] [Abstract][Full Text] [Related]
16. Combination of Thymoquinone and Intermittent Fasting as a Treatment for Breast Cancer Implanted in Mice.
Haif SK; Al Kury LT; Talib WH
Plants (Basel); 2023 Dec; 13(1):. PubMed ID: 38202341
[TBL] [Abstract][Full Text] [Related]
17. A dual role for Caspase8 and NF-
Hernandez L; Kim MK; Noonan AM; Sagher E; Kohlhammer H; Wright G; Lyle LT; Steeg PS; Anver M; Bowtell DD; ; Annunziata CM
Cell Death Discov; 2015; 1():15053. PubMed ID: 28179987
[TBL] [Abstract][Full Text] [Related]
18. Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancer.
Liao JB; Ovenell KJ; Curtis EE; Cecil DL; Koehnlein MR; Rastetter LR; Gad EA; Disis ML
J Immunother Cancer; 2015; 3():16. PubMed ID: 25992288
[TBL] [Abstract][Full Text] [Related]
19. Ascites exosomal lncRNA PLADE enhances platinum sensitivity by inducing R-loops in ovarian cancer.
Liu H; Deng S; Yao X; Liu Y; Qian L; Wang Y; Zhang T; Shan G; Chen L; Zhou Y
Oncogene; 2024 Mar; 43(10):714-728. PubMed ID: 38225339
[TBL] [Abstract][Full Text] [Related]
20. Effect of cisplatin upon expression of in vivo immune tumor resistance.
Crum ED
Cancer Immunol Immunother; 1993; 36(1):18-24. PubMed ID: 8422664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
